What’s News in Markets: Amgen’s Prognosis, Quantum Boost, iPhone Makeover
Why did a failed Novartis drug trial tank Amgen’s shares? And how is taxpayer money funding quantum-computing companies? Plus, will people pay $2,000 for a foldable iPhone? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter.…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from WSJ What’s News
See all episodes →Similar episodes from other shows
More like WSJ What’s News →
Netflix Shares Drop After Earnings, and the Top Biotech Analyst Dissects the Race for a COVID Cure
The Cancer Vaccine That Could Save Moderna
Arm wrestles with bad first quarter as a public company
Apple Rethinks the iPhone
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.